Neuraxis

Neuraxis EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Neuraxis (NRXS) as of Nov 16, 2026 is -6.10. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -6.37 — a change of -4.19% (higher).

EV/EBITDA

-6.10

YoY

-4.19%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Neuraxis is 2025 -6.10 . EV/EBITDA (Enterprise Value to EBITDA) of Neuraxis was 2024 -6.37 . It decreases by -4.19% higher compared to the previous year.

The Neuraxis EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2020
-12.31 USD
Jan 1, 2021
-17.53 USD
Jan 1, 2022
-12.07 USD
Jan 1, 2023
-7.87 USD
Jan 1, 2024
-6.37 USD
Jan 1, 2025
-6.10 USD
The Neuraxis EV/EBITDA history
YEAREV/EBITDAYoY
-6.10-4.19%
-6.37-19.11%
-7.87-34.79%
-12.07-31.14%
-17.53+42.39%
-12.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

EV/EBITDA (Enterprise Value to EBITDA) of Neuraxis is -6.10 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Neuraxis changed from -6.37 to -6.10, representing a -4.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Neuraxis since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Neuraxis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neuraxis

All Key Metrics — Neuraxis